Article information

Korean J Otorhinolaryngol-Head Neck Surg. 2021;64(12):954-958

Publication date (electronic) : 2021 December 21

doi : https://doi.org/10.3342/kjorl-hns.2021.00269

Seulki Song¹, Dae Hyun Song², Jin Pyeong Kim^,1

¹Department of Otorhinolaryngology-Head and Neck Surgery, Gyeongsang National University College of Medicine, Gyeongsang National University Changwon Hospital, Changwon, Korea

²Department of Pathology, Gyeongsang National University College of Medicine, Institute of Health Science, Gyeongsang National University Changwon Hospital, Changwon, Korea

송슬기¹, 송대현², 김진평^,1

¹경상국립대학교 의과대학 이비인후과학교실, 창원경상국립대학교병원

²경상국립대학교 의과대학 병리학교실, 경상국립대학교 건강과학연구원

Address for correspondence Jin Pyeong Kim, MD, PhD Department of Otorhinolaryngology-Head and Neck Surgery, Gyeongsang National University College of Medicine, Gyeongsang National University Changwon Hospital, 11 Samjeongja-ro, Seongsan-gu, Changwon 51472, Korea Tel +82-55-214-2799 Fax +82-55-214-1410 E-mail jinpyeong@gnu.ac.kr

Received 2021 April 10; Revised 2021 June 20; Accepted 2021 June 28.

Trans Abstract

Introduction

Sarcomas account for less than 1% of head and neck malignancies [1]. Head and neck sarcomas represent only 5%-15% of all sarcomas in adults [2]. The most common histologic types of sarcomas in the head and neck region are rhabdomyosarcoma, osteosarcoma, malignant fibrous histiocytoma (MFH), and angiosarcoma.

Myxofibrosarcoma (MFS) is a histologic subtype of MFH that has been previously confused with multiple entities of MFH. The rapid development of immunohistochemical and genetic/molecular studies have established a distinct diagnosis of MFS [3]. However, due to the rarity of MFS, the clinical behavior and outcome of MFS tumors are uncertain; moreover, there are no randomized clinical trials to establish treatment guidelines [4].

Herein, we report a case of MFS on a false vocal fold, with the patient presenting with voice changes and progressive dyspnea. To our knowledge, this is the first case of high-grade MFS in the larynx with an epithelioid variant.

Case

A 79-year-old male presented to our outpatient clinic with complaints of change in his voice that began one month prior. The patient had no history of smoking or prior irradiation. He suffered from hypertension, diabetes, and cerebrovascular disease with severe stenosis. Laryngoscopic examination revealed a mass-like lesion on the left false vocal fold (Fig. 1A), with intact vocal fold mobility. There were no abnormal findings on esophagogastroduodenoscopy. Initial CT and MRI of the neck revealed a heterogeneously enhancing mass in the left false vocal fold and aryepiglottic fold, with invasion of the paraglottic fat (Fig. 1B and C). However, no definite metastatic lymph node was identified in the neck, bilaterally. Rigid laryngoscopy and punch biopsy of the left false vocal fold mass were performed under general anesthesia. Punch biopsy revealed a spindle cell sarcoma with a myxoid component, suggestive of MFS. There was no distant lesion on positron emission tomography. Even with enough consultation, the patient wanted radiotherapy as a primary treatment. Soon after referring to radiation oncologist, the patient visited the emergency room for dyspnea 5 days after rigid endoscopy and underwent emergent tracheostomy. As the tumor was large and aggressively growing, with involvement of the paraglottic space, and considering patient’s characteristics (old age, poor pulmonary function, and multiple co-morbidities), total laryngectomy was performed 1 week after the tracheostomy. Final histopathology confirmed a high-grade MFS, with a maximum tumor diameter of 3 cm. The tumor was composed of spindle cells with a myxoid background (Fig. 2A and B), which did not react with cytokeratin antibody (Fig. 2C). Immunohistochemical staining using vimentin and CD31 was positive (Fig. 2D and E). Partial epithelioid features were identified with vascular invasion (Fig. 3). The aforementioned pathologic results were consistent with a high-grade epithelioid variant MFS. The patient was discharged 14 days after surgery without complications and was followed up for 4 months with no tumor recurrence.

Fig. 1.

Preoperative evaluation. A: Laryngoscopic finding, showing a protruding mass in the left false vocal fold. B and C: Preoperative CT image (B) and MR image (C) showing a heterogeneously enhanced mass in the left false vocal fold and aryepiglottic fold, extending to the paraglottic fat.

Fig. 2.

Postoperative histopathologic and immunohistochemical findings of myxofibrosarcoma. A: The tumor consisted of spindle cells with a myxoid background; elongated, curvilinear, and thin-walled blood vessels are observed among spindle tumor cells (H&E stain, ×40). B: Spindle cells showing enlarged hyperchromatic nuclei with eosinophilic cytoplasm (H&E stain, ×100). C: Spindle tumor cells with no reaction to cytokeratin antibody (pan cytokeratin, ×100). D: Tumor cells with positivity to vimentin antibody (vimentin, ×100). E: CD31 immunohistochemical stain highlighting distinctive curvilinear blood vessels (CD31, ×100). H&E, hematoxylin and eosin.

Fig. 3.

Postoperative histopathologic and immunohistochemical findings of epithelioid variance. A: Typical histologic background of myxofibrosarcoma (arrowheads) with a partial epithelioid variant (arrows) (H&E stain, ×40). B: Higher power imaging of the region of the epithelioid variant (H&E stain, ×200). C: The epithelioid variant portion showing positivity to vimentin antibody (vimentin, ×200). H&E, hematoxylin and eosin.

Discussion

MFS was firstly described as a “myxoid variant of MFH” by Weiss and Enzinger [5] in 1977. They reported that the myxoid variant of MFH exhibited a better prognosis than other forms of MFH tumors [5]. Owing to various efforts to distinguish MFS from a variety of histological types of MFH, as well as advances in immunohistochemistry and molecular techniques, the 2013 World Health Organization Classification of Tumors of Soft Tissue and Bone recommended the use of the term MFS instead of myxoid variant MFH[3]. Patients presenting with MFS are generally 50 to 70 years of age and are more commonly men [6]. The most common site of involvement is the extremities (77%), with an incidence rate of 3% in the head and neck region [6-8]. Owing to the multidirectional spread of MFS along the facial planes and its infiltrative growth pattern, obtaining a clear surgical margin may be challenging [4]. For this reason, MRI is the diagnostic modality of choice to identify the extent of the tumor preoperatively [4]. Surgical resection is the treatment of choice for patients presenting with MFS. There is no randomized controlled study specific to MFS evaluating the treatment outcome of surgery compared to radiotherapy. The national comprehensive cancer network (NCCN) clinical practice guideline in soft tissue sarcoma recommends surgical wide excision as a primary treatment option when soft tissue sarcoma in head and neck is resectable[8]. And one retrospective study reported the patients treated with radiotherapy had the same prognosis as untreated patients. Although radiotherapy as a definitive treatment in MFS seems to have poor oncologic outcome, the neo-adjuvant or adjuvant therapies with surgery have a benefit of reducing potential local and distant recurrences [4].

MFS has a relatively better prognosis than the other histological subtypes of sarcomas, such as leiomyosarcoma, with the 5-year overall survival ranging from 61% to 82.6% [4,9]. However, MFS is a locally aggressive tumor with a high rate of local recurrence of 16%-57% and with a median time to recurrence of 8.2-27 months [4,9,10]. For this reason, wide resection, including a 2 cm free margin from the tumor, is recommended. Prognostic factors have been investigated, with inadequate surgical resection margins, large tumor size, old age, and high-grade histology found to be significant poor prognostic factors for overall survival [9,10].

Various grading systems have been developed for MFS, with the French Federation of Cancer Centers Sarcoma Group system and the National Cancer Institute system being the most widely recognized. These systems include three groups of soft tissue sarcomas, as low-, intermediate-, and high-grade [11,12]. The recurrence rate of high-grade tumors is 62%, which is higher than the rate for low-grade tumors (48%) [4]. Rarely, epithelioid cells, rather than spindle cells, can be observed within the myxoid area of the MFS, with the epithelioid variant of MFS having a poor prognosis compared to traditional spindle cell MFS. Nascimento, et al. [13] reported the epithelioid variant to be more aggressive than the traditional spindle cell MFS, with a rate of local recurrence of 70% and a rate of metastases of 50%. Scoccianti, et al. [9] reported the presence of an epithelioid variant pattern as a negative prognostic factor for disease-specific survival, local recurrence free survival, and metastases free survival. In fact, the reported rate of disease-specific survival of 53.6% for the epithelioid subtype of MFS is markedly lower than the survival rate for low-grade (100%) and high-grade (77.7%) tumors [9].

Gugatschka, et al. [14] reported a low-grade MFS in the unilateral vocal fold, which was completely excised by laser cordectomy, with a clear surgical margin. Ocak, et al. [15] reported an intermediate-grade MFS on the arytenoid mucosa, with a positive surgical margin achieved after surgery. Our case is the first report of a high-grade MFS with an epithelioid variant in the larynx. In fact, the previously reported laryngeal MFH might be MFS. However, the concept of MFS has been affirmed since 2002, and the cases of MFS in the larynx are extremely rare since then.

Owing to the unique anatomical features of the larynx, wide resection of the tumor with a clear resection margin may be difficult to perform due to the critical negative effect on function, including speech and swallowing. In such cases, free flap reconstruction may be essential. Considering the generally favorable survival outcome for these tumors in relation to the negative impact of wide resection on function, the extent of initial surgery for laryngeal MFS is an issue of controversy. However, owing to the high rate of local recurrence of MFS, wide excision with a clear surgical margin may still be the treatment of choice. In our case, 1) the tumor was aggressively growing and involved the paraglottic space, and 2) the patient had old age, poor pulmonary condition, frequent aspiration tendency, and multiple co-morbidities. Roland, et al. [4] recommends wide surgical resection with a 2 cm soft tissue margin from the area of enhanced signal on T2-weighted MRI, and NCCN guideline also recommends special consideration of resection margin in the infiltrative histologies such as MFS, dermatofibrosarcoma protuberans, and angiosarcoma; therefore, total laryngectomy was inevitable to obtain a clear surgical margin. Final pathologic reports with high-grade and epithelioid variant MFS revealed total laryngectomy might be better option than laryngeal-preserving surgery. Unfortunately, we could not evaluate therapeutic outcome due to too much short follow period, long-term observation is required. Most of laryngeal malignancies originates from epithelium. Laryngeal sarcomas are relatively rare and MFS in the larynx is extremely rare. It is difficult to evaluate the treatment outcome of MFS in the larynx because there have been few studies. Still, much wider excision of tumor in MFS may be recommended than in carcinoma for better local control. Further study is required to elucidate a proper treatment.

Article information Continued